Vical Joins Forces With Astellas On CMV Vaccine
This article was originally published in PharmAsia News
Executive Summary
Vaccine-focused biotech Vical Inc. announced July 14 that it has inked a global licensing agreement with Japan's Astellas Pharma Inc. to develop and commercialize the biotech's cytomegalovirus (CMV) vaccine, TransVax